Lexapro Withdrawal Symptoms and Tapering Strategy
Lexapro (escitalopram) should be tapered gradually over weeks to months rather than stopped abruptly, as discontinuation syndrome occurs commonly and can include dizziness, sensory disturbances, anxiety, irritability, headache, nausea, and flu-like symptoms that may last days to months if not properly managed. 1
Withdrawal Symptoms
Common discontinuation symptoms include:
- Neurological symptoms: Dizziness (44%), sensory disturbances including paresthesias and "electric shock" sensations, headache, confusion, trouble concentrating, amnesia (28%) 2, 1, 3
- Psychiatric symptoms: Anxiety, irritability, agitation, emotional lability, dysphoric mood, crying (28%) 2, 1, 3
- Physical symptoms: Muscle tension (44%), chills (44%), fatigue, lethargy, general malaise, myalgias, nausea, vomiting, diarrhea 2, 1, 3
- Sleep disturbances: Insomnia 2, 1, 4
- Balance issues: Imbalance, vertigo 2
Important clinical distinction: While escitalopram/citalopram have relatively lower risk compared to paroxetine, fluvoxamine, and sertraline for discontinuation syndrome, symptoms still occur frequently and can be severe 2. One study found discontinuation syndrome in 56% (14 of 25 patients) who stopped escitalopram 3.
Risk Factors for Severe Withdrawal
Higher doses and higher plasma concentrations of escitalopram significantly increase the risk of discontinuation syndrome 3. Patients on higher doses require even more gradual tapering. Duration of treatment does not appear to correlate with withdrawal severity 3.
Tapering Protocol
The FDA-approved label and clinical guidelines recommend gradual dose reduction rather than abrupt cessation 2, 1. However, standard recommendations for 2-4 week tapers are inadequate and often not tolerated 5.
Evidence-based tapering approach:
Taper over months, not weeks: Standard short tapers (2-4 weeks) show minimal benefit over abrupt discontinuation 5. Tapers over several months have greater success in reducing withdrawal symptoms 5, 6
Use hyperbolic (exponential) tapering, not linear: Reduce doses hyperbolically to maintain consistent reductions in serotonin transporter occupancy 5. Linear dose reductions cause disproportionately large drops in receptor occupancy at lower doses, triggering withdrawal 5
Taper to doses far below minimum therapeutic levels: Continue tapering to very small doses (much lower than the 10 mg minimum therapeutic dose) before complete cessation 5, 6
Specific reduction schedule: Start with 10% reductions of the current dose (not the original dose) every 2-4 weeks, slowing further as doses decrease 6. Some patients require reductions as small as 5% or slower 2
Critical pitfall to avoid: Do NOT use alternate-day dosing as a tapering strategy. Dosing every other day causes pronounced fluctuations in receptor occupancy that trigger withdrawal symptoms, even at doses above the therapeutic minimum 7. This common practice should be abandoned in favor of daily dosing at gradually reduced amounts 7.
Managing Withdrawal Symptoms
If intolerable symptoms emerge:
- Reinstate the previous dose that was tolerated, then resume tapering at a slower rate 1, 4
- Provide symptomatic management for specific symptoms (e.g., antiemetics for nausea) 4
- Reassure patients that symptoms are time-limited and represent withdrawal, not relapse of underlying depression 4, 8, 9
Protracted withdrawal syndrome: Some patients experience symptoms lasting months after complete discontinuation 8, 6. These delayed or persistent symptoms should not automatically be interpreted as relapse but may represent prolonged withdrawal 4, 9.
Monitoring Requirements
Monitor closely for:
- Emergence of withdrawal symptoms during dose reductions 1
- Differentiation between withdrawal symptoms and relapse of underlying condition 4, 8
- Suicidal thoughts or behaviors, particularly in young adults, as discontinuation itself can be a period of vulnerability 1
Patient education is essential: Inform patients that withdrawal symptoms are common, expected, and do not indicate treatment failure or inability to stop the medication 4, 9. Clear communication reduces nocebo effects and anxiety about the tapering process 9.